News Focus
News Focus
icon url

jesster64

10/26/25 12:58 AM

#794786 RE: GoodGuyBill #794778

You're absolutely right. We will be approved for tissue agnostic worth billions, we will have a short squeeze worth billions, and lawsuit will net us billions. Believe what you want, no use talking sense to pushers or fudsters.
"Deny what’s plainly in front of you."
Whats plainly in front of me and the world is SP at less than .25
But pushers on this board are clearly smarter than millions of investors around the world.
icon url

jesster64

10/26/25 1:06 AM

#794788 RE: GoodGuyBill #794778

"Show me where I put words in Smyth's mouth."

"Her reply echoed that scope of language. It was NOT a denial of DCVax-L's broader potential or mechanism of actions across caner types."

Implying she didn't mean it was only for glioblastoma, which she did, is putting words (or alternate meaning) in her mouth.
show me where she uses the word "scope"

"You're the one interpreting what she "meant"- not me."
what she said was "for glioblastoma", how am I interpreting that wrong. ?

"So why won’t you acknowledge that this mechanism directly supports the position that DCVax-L is cancer agnostic?"
It very well may be, but they only applied for glioblastoma.
icon url

exwannabe

10/26/25 12:17 PM

#794853 RE: GoodGuyBill #794778

Furthermore, if the MHRA can’t expand beyond the applied indication, then explain how DCVax-L ended up on the High-Cost Drug list with an expanded indication.


The list has many entries that simply state "cancer" as the indication w/o specifying. And all the others are not tumor agnostic.

The list.

The column is just descriptive. It does not decide what is actually approved. If a drug on this list is approved, then the provider can try to get reimbursement for using it per the terms. The least useful process is the IFR that allows a patient to say why they are somehow different and thus should be entitled to have the drug paid for.
icon url

attilathehunt

10/26/25 12:55 PM

#794864 RE: GoodGuyBill #794778

if the MHRA can’t expand beyond the applied indication, then explain how DCVax-L ended up on the High-Cost Drug list with an expanded indication. That didn’t happen by accident.



Get ready for explosions!

Once approval hits, major publications in the UK will ignite a world-wide firestorm of free press.

The world will know....The demand, to be an owner of our gem, will be unprecedented!

We will hear the following key words in articles from around the world....Agnostic, Breakthrough, Cure, Dominate, Eden, Freedom, Gratitude, Hope, Innovation, Joy, Kindness, Life, Miracle, NWBO, Optimism, Partnership(s), Quality, Roswell, Shorts-eat-shit, Tumor, Unbelievable, Validation, Worldwide, Xenogeneic, Yield, Zero cancer!!!!!

Are you ready? I am!!!!!